Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapeutics for neurodegenerative and autoimmune diseases.

Its lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody in clinical development worldwide, administered via a proprietary nasal mucosal delivery route to modulate T-cell activity.

Clinical programmes target secondary progressive multiple sclerosis, multiple system atrophy, Alzheimer's disease, and amyotrophic lateral sclerosis.

The pipeline also includes Milciclib, a CDK inhibitor in oncology.